Anticipated Financial Report of Danaher: Crucial Facts to Consider
In the upcoming fiscal second-quarter earnings announcement on Tuesday, Jul. 22, Danaher Corporation (DHR) is projected to report earnings per share (EPS) of approximately $1.64, representing a decline of about 4.7% from $1.72 per share in the same quarter last year.
Despite this modest decrease, analysts maintain a bullish consensus opinion on DHR, with an overall “Strong Buy” rating. This optimistic outlook reflects confidence in DHR's growth prospects, despite near-term headwinds such as tariffs and academic budget cuts.
For the full fiscal year 2025, Danaher has reaffirmed its guidance, with adjusted diluted EPS expected in the range of $7.60 to $7.75. This figure closely aligns with analysts' consensus of around $7.68 to $7.70. For the full year 2025, analysts forecast an EPS of $7.70, which would be a 2.9% increase from $7.48 in fiscal 2024, and a further rise to $8.58 in fiscal 2026.
DHR's strong position in bioprocessing growth and stable demand in other segments, despite some macroeconomic pressures, support this positive sentiment. The Danaher Corporation, based in the District of Columbia, designs, manufactures, and markets professional, medical, research, and industrial products and services.
Out of 23 analysts covering the stock, 18 advise a "Strong Buy" rating, one suggests a "Moderate Buy," and four give a "Hold." The average analyst price target is $243, indicating a potential upside of 23% from the current levels.
DHR has demonstrated strong performance in recent quarters, beating the consensus estimates in three of the last four quarters. On Apr. 22, DHR shares closed up more than 3%. On Mar. 3, DHR announced its fiscal first-quarter earnings, with an adjusted EPS of $1.88, surpassing Wall Street expectations of $1.62.
It is important to note that all information and data in this article is solely for informational purposes. Neha Panjwani did not have positions in any of the securities mentioned in the article. For more information, please view the Disclosure Policy on the website.
With a market cap of $142.3 billion, DHR remains a significant player in the industry. Investors will be closely watching the company's Q2 2025 earnings announcement for further insights into its performance and future prospects.
Personal-finance analysts maintain a bullish consensus on DHR's investing potential, with the majority advising a "Strong Buy" rating. This positive sentiment is based on DHR's growth prospects, including its strong position in bioprocessing and other segments, despite macroeconomic pressures.
